Drug Type TIL therapy |
Synonyms GC101 TIL |
Target- |
Action- |
Mechanism T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 25 Mar 2026 | |
| Unresectable Melanoma | Phase 2 | China | 20 Dec 2024 | |
| Uveal Melanoma | Phase 2 | China | 20 Dec 2024 | |
| Metastatic melanoma | Phase 2 | China | 08 Nov 2023 | |
| metastatic non-small cell lung cancer | Phase 1 | China | 14 Oct 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 12 Oct 2022 |
Phase 2 | Refractory Melanoma Last line | 98 | GC101 TIL therapy | efdnoajqmt(oposzjqdgp) = rilhgdnblk sxapumegki (febmtrnurp ) View more | Positive | 05 Dec 2025 | |
Investigator-choice chemotherapy | efdnoajqmt(oposzjqdgp) = kqvjhotqpe sxapumegki (febmtrnurp ) View more | ||||||
Company_Website Manual | Not Applicable | Melanoma KRAS Mutation (Activating) | 1 | qdojahcjkl(njmznvuipr) = swrcdazcjf zntlciipuq (rhaqwuirxs ) View more | Positive | 18 Jul 2025 | |
Phase 1 | Non-Small Cell Lung Cancer ROS1 Positive | 2 | GC101 (ROS1融合阳性) | ecasrlhrct(qzebwhvkbo) = Group1接受GC101 TIL单次回输后,该患者除了短暂的一过性发热和血象降低,无其他不良反应。 atflvhbeaw (uykhoklgol ) View more | Positive | 13 Dec 2024 | |
GC101 (KRAS G12D) |





